Free Trial
NASDAQ:TLSIW

TriSalus Life Sciences (TLSIW) Stock Price, News & Analysis

TriSalus Life Sciences logo
$1.31 +0.10 (+8.26%)
As of 01/21/2025 11:34 AM Eastern

About TriSalus Life Sciences Stock (NASDAQ:TLSIW)

Key Stats

Today's Range
$1.03
$1.41
50-Day Range
$0.91
$1.31
52-Week Range
$0.81
$2.23
Volume
11,649 shs
Average Volume
2,771 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

Receive TLSIW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TriSalus Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

TLSIW Stock News Headlines

Did You See Trump’s Manhattan Project Bombshell?
This secret document contains stunning details about Donald Trump’s very first order of business… the minute he steps back into the White House. Because if what’s in this leaked document is even half true (and trust me, it comes from a very, very credible source)... Trump’s first Executive Order would easily be the boldest, most mind-blowing and daring American initiative ANY U.S. President has launched in over 80 years.
TriSalus Life Sciences Taps James Young as CFO
TriSalus Announces Leadership Changes
TriSalus Life Sciences appoints James Young CFO, Richard Marshak CCO
JonesTrading Remains a Buy on TriSalus Life Sciences (TLSI)
See More Headlines

TLSIW Stock Analysis - Frequently Asked Questions

TriSalus Life Sciences' stock was trading at $1.10 at the beginning of 2025. Since then, TLSIW shares have increased by 19.1% and is now trading at $1.31.
View the best growth stocks for 2025 here
.

Shares of TLSIW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:TLSIW
Fax
N/A
Employees
106
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$26.89 million

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NASDAQ:TLSIW) was last updated on 1/22/2025 by MarketBeat.com Staff
From Our Partners